Arrowhead Pharmaceuticals (ARWR) Competitors $19.90 -1.06 (-5.06%) Closing price 04:00 PM EasternExtended Trading$19.91 +0.01 (+0.05%) As of 07:27 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrends ARWR vs. QGEN, ASND, ROIV, RVMD, LEGN, BBIO, AXSM, BPMC, TLX, and ELANShould you be buying Arrowhead Pharmaceuticals stock or one of its competitors? The main competitors of Arrowhead Pharmaceuticals include Qiagen (QGEN), Ascendis Pharma A/S (ASND), Roivant Sciences (ROIV), Revolution Medicines (RVMD), Legend Biotech (LEGN), BridgeBio Pharma (BBIO), Axsome Therapeutics (AXSM), Blueprint Medicines (BPMC), Telix Pharmaceuticals Limited American Depositary Shares (TLX), and Elanco Animal Health (ELAN). These companies are all part of the "pharmaceutical products" industry. Arrowhead Pharmaceuticals vs. Qiagen Ascendis Pharma A/S Roivant Sciences Revolution Medicines Legend Biotech BridgeBio Pharma Axsome Therapeutics Blueprint Medicines Telix Pharmaceuticals Limited American Depositary Shares Elanco Animal Health Qiagen (NYSE:QGEN) and Arrowhead Pharmaceuticals (NASDAQ:ARWR) are both mid-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their risk, analyst recommendations, valuation, earnings, institutional ownership, profitability, media sentiment, dividends and community ranking. Which has more risk & volatility, QGEN or ARWR? Qiagen has a beta of 0.36, suggesting that its share price is 64% less volatile than the S&P 500. Comparatively, Arrowhead Pharmaceuticals has a beta of 0.95, suggesting that its share price is 5% less volatile than the S&P 500. Does the media favor QGEN or ARWR? In the previous week, Arrowhead Pharmaceuticals had 10 more articles in the media than Qiagen. MarketBeat recorded 22 mentions for Arrowhead Pharmaceuticals and 12 mentions for Qiagen. Arrowhead Pharmaceuticals' average media sentiment score of 0.35 beat Qiagen's score of -0.37 indicating that Arrowhead Pharmaceuticals is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Qiagen 1 Very Positive mention(s) 1 Positive mention(s) 5 Neutral mention(s) 2 Negative mention(s) 1 Very Negative mention(s) Neutral Arrowhead Pharmaceuticals 3 Very Positive mention(s) 2 Positive mention(s) 6 Neutral mention(s) 1 Negative mention(s) 1 Very Negative mention(s) Neutral Do analysts recommend QGEN or ARWR? Qiagen presently has a consensus target price of $47.71, indicating a potential upside of 20.73%. Arrowhead Pharmaceuticals has a consensus target price of $41.44, indicating a potential upside of 108.26%. Given Arrowhead Pharmaceuticals' stronger consensus rating and higher possible upside, analysts clearly believe Arrowhead Pharmaceuticals is more favorable than Qiagen.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Qiagen 0 Sell rating(s) 7 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 2.30Arrowhead Pharmaceuticals 0 Sell rating(s) 4 Hold rating(s) 6 Buy rating(s) 0 Strong Buy rating(s) 2.60 Do institutionals & insiders have more ownership in QGEN or ARWR? 70.0% of Qiagen shares are owned by institutional investors. Comparatively, 62.6% of Arrowhead Pharmaceuticals shares are owned by institutional investors. 9.0% of Qiagen shares are owned by insiders. Comparatively, 4.3% of Arrowhead Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term. Does the MarketBeat Community prefer QGEN or ARWR? Arrowhead Pharmaceuticals received 300 more outperform votes than Qiagen when rated by MarketBeat users. Likewise, 65.51% of users gave Arrowhead Pharmaceuticals an outperform vote while only 60.29% of users gave Qiagen an outperform vote. CompanyUnderperformOutperformQiagenOutperform Votes24960.29% Underperform Votes16439.71% Arrowhead PharmaceuticalsOutperform Votes54965.51% Underperform Votes28934.49% Is QGEN or ARWR more profitable? Qiagen has a net margin of 4.23% compared to Arrowhead Pharmaceuticals' net margin of 0.00%. Qiagen's return on equity of 13.92% beat Arrowhead Pharmaceuticals' return on equity.Company Net Margins Return on Equity Return on Assets Qiagen4.23% 13.92% 8.40% Arrowhead Pharmaceuticals N/A -236.60%-64.09% Which has better earnings and valuation, QGEN or ARWR? Qiagen has higher revenue and earnings than Arrowhead Pharmaceuticals. Arrowhead Pharmaceuticals is trading at a lower price-to-earnings ratio than Qiagen, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioQiagen$1.98B4.43$83.59M$0.36110.03Arrowhead Pharmaceuticals$3.55M706.87-$599.49M-$5.17-3.85 SummaryQiagen and Arrowhead Pharmaceuticals tied by winning 9 of the 18 factors compared between the two stocks. Get Arrowhead Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for ARWR and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart ARWR vs. The Competition Export to ExcelMetricArrowhead PharmaceuticalsPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$2.51B$7.04B$5.78B$8.98BDividend YieldN/A2.87%4.78%3.85%P/E Ratio-3.856.1326.4618.82Price / Sales706.87313.46457.9780.74Price / CashN/A67.8344.0437.47Price / Book45.236.747.634.64Net Income-$599.49M$138.11M$3.18B$245.69M7 Day Performance-0.25%-2.02%-1.82%-2.63%1 Month Performance0.71%-1.54%0.22%-2.37%1 Year Performance-31.80%-3.14%17.49%13.65% Arrowhead Pharmaceuticals Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)ARWRArrowhead Pharmaceuticals4.1029 of 5 stars$19.90-5.1%$41.44+108.3%-28.3%$2.51B$3.55M-3.85400QGENQiagen4.4279 of 5 stars$39.85-0.5%$48.78+22.4%-7.3%$8.84B$1.98B110.975,967Analyst DowngradeASNDAscendis Pharma A/S3.1758 of 5 stars$144.08+1.1%$193.43+34.3%-1.4%$8.74B$288.08M-17.83640Analyst ForecastROIVRoivant Sciences2.7251 of 5 stars$10.56+1.1%$18.08+71.2%-7.1%$7.69B$124.79M1.87860Insider TradeRVMDRevolution Medicines4.5108 of 5 stars$40.67-1.6%$66.25+62.9%+44.9%$6.84B$11.58M-11.33250LEGNLegend Biotech2.5939 of 5 stars$36.42+0.1%$79.50+118.3%-35.2%$6.65B$285.14M-38.341,800Positive NewsBBIOBridgeBio Pharma4.7193 of 5 stars$34.90+10.6%$49.08+40.6%+2.4%$6.60B$9.30M-14.48400Earnings ReportAnalyst ForecastInsider TradeNews CoverageGap UpAXSMAxsome Therapeutics4.5264 of 5 stars$131.15-0.4%$147.13+12.2%+59.2%$6.36B$270.60M-20.08380Earnings ReportAnalyst ForecastAnalyst RevisionNews CoverageBPMCBlueprint Medicines2.9925 of 5 stars$93.94-1.3%$123.83+31.8%+3.4%$5.97B$249.38M-44.52640Earnings ReportTLXTelix Pharmaceuticals Limited American Depositary SharesN/A$17.19-0.6%$22.00+28.0%N/A$5.79B$637.08M0.00N/ANews CoverageGap UpELANElanco Animal Health4.0563 of 5 stars$11.26-3.4%$16.29+44.7%-31.0%$5.57B$4.42B28.159,300Analyst Forecast Related Companies and Tools Related Companies Qiagen Alternatives Ascendis Pharma A/S Alternatives Roivant Sciences Alternatives Revolution Medicines Alternatives Legend Biotech Alternatives BridgeBio Pharma Alternatives Axsome Therapeutics Alternatives Blueprint Medicines Alternatives Telix Pharmaceuticals Limited American Depositary Shares Alternatives Elanco Animal Health Alternatives Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:ARWR) was last updated on 2/21/2025 by MarketBeat.com Staff From Our PartnersCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | SponsoredElon “obliterates” Bill Gates?All 10 of the world's biggest money managers follow my work, and the Pentagon, the FBI and Harvard professors ...Altimetry | SponsoredNVDA Crash UpdateAn overseas AI rival sent shockwaves through the U.S. tech market last week... Leaving millions of investor...Chaikin Analytics | SponsoredHas Trump finally met his match?Dylan Jovine predicted the 2008 crash over a year before it happened. Folks who listened to him had the chance...Behind the Markets | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | Sponsored Is Starlink Set For The Largest IPO In History?He turned PayPal from a tiny, off-the-radar startup… to a massive $64 billion giant. Then, he did it again ...Paradigm Press | Sponsored My 2025 AI BlueprintI first recommended Bitcoin at $300 in 2013 … before it went up 33,645%. Now, I am revealing my 2025 AI Blu...Weiss Ratings | SponsoredBetter than Bitcoin – and potentially more profitableThe world is obsessed with Bitcoin again... And for a good reason: It just soared beyond $100,000. Bitcoin ...Brownstone Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Arrowhead Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Arrowhead Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free ARWR Stock Alerts